Acknowledgement
Supported by : 질병관리본부
References
- Ward JI. Haemophilus influenzae. In: Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, editors. Textbook of Pediatric Infectious Disease. 5th ed. WB Saunders Co, 2004:1636-55
- Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002. J Pediatr 2003;143Suppl 6:163-87
- Lee HJ, Kim CH, Park CY, Shon YM, Oh SH, Chun CS, et al. Natural antibody against Haemophilus influenzae type b in a sample population of Korean children. J Korean Pediatr Soc 1993;36:1471-7
- Yoo ES, Park EA, Kim GH. Natural anti-PRP antibody level to Haemophilus influenza type b (Hib) and change of antibody level after three doses of vaccination. J Korean Pediatr Soc 1995;38:1201-9
- Kim JS, Cho SB, Lee HR, Park SK, Hwang PH. Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) in Korean infants. Korean J Infect Dis 1996;28:225-32 https://doi.org/10.3109/00365549609027161
- Yang PS, Seo JI, Noh KT, Yoo JH, Hwang KS, Hwang KG. Studies of the change of antibody titers after vaccination of Haemophilus influenzae PRP-T conjugate vaccine. J Korean Pediatr Soc 2002;45:987-93
- Chung EH, Kim YJ, Kim YK, Kim DH, Seo JW, Lee HJ. Immunogenicity and safety of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T; HiberixTM) in Korean infants. J Korean Pediatr Infect Dis 2003;10:71-80
- World Health Organization. WHO Position Paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec 2006;81:445-52
- WHO/UNICEF coverage estimates, 1980-2005, as of August 2006 192 WHO Member States. Date of slide: 19 October 2006. Available from: URL://http://www.who.int/nuvi/ hib/slides/Products01.pdf
- Korean Pediatric Society, Committee on Infectious Diseases. Guideline for immunization in Korean infants and children. 5th edition, Kwang Moon Press, Seoul, Korea, 2002 p163-80
- Kim KH, Park HS, Park BH, Kong KE, Kim OS, Paik SH, et al. A study of immunization rate in children of 2 year of age for intervention of immunization in local society. Program and Abstract. The Annual Fall Meeting of the Korean Society of Pediatric Infectious Diseases; 2006 Nov 11; Seoul. Seoul: The Korean Society of Pediatric Infectious Diseases, 2006:6
- Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev 2003;(4):CD001729
- Ward J, Brenneman G, Letson GW, Heyward WL. The Alaska H. influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990;323:1393-401 https://doi.org/10.1056/NEJM199011153232006
- Petersen GM, Silimperi DR, Rotter JI, Terasaki PI, Schanfield MS, Park MS, et al. Genetic factors in Haemophilus influenzae type b disease susceptibility and antibody acquisition. J Pediatr 1987;110:228-33 https://doi.org/10.1016/S0022-3476(87)80159-2
- Cryz SJ Jr, Furer E, Fredeking T, Cross AS, Sadoff JC, Que JU. Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines. Lancet 1989;23:1533-4
- Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990;135:121-8 https://doi.org/10.1016/0022-1759(90)90264-V
- Madore DV, Anderson P, Baxter BD, Carlone GM, Edwards KM, Hamilton RG, et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996;3:84-8
- Romero-Steiner S, Fernandez J, Biltoft C, Wohl ME, Sanchez J, Feris J, et al. Functional antibody activity elicited by fractional doses of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate). Clin Diagn Lab Immunol 2001;8:1115-9
- Kim KH, Kang JH, Kim JS, Kim JH, Park SE, Park EA, et al. A study for immunization schedule assessment of Hib vaccine in Korea. Program and Abstract. the 55th Annual Fall Meeting of the Korean Pediatric Society; 2005 Oct 21-22; Seoul. Seoul: The Korean Pediatric Society, 2005:68
- Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992;121:187-94 https://doi.org/10.1016/S0022-3476(05)81186-2
- Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62 https://doi.org/10.1016/S0022-3476(05)81786-X
- Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994;344: 362-6 https://doi.org/10.1016/S0140-6736(94)91400-1
- Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324:1767-72 https://doi.org/10.1056/NEJM199106203242503
- Harrison LH, Tajkowski C, Croll J, Reid R, Hu D, Brenneman G, et al. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 1994;125:571-6 https://doi.org/10.1016/S0022-3476(94)70009-5
- Goldblatt D, Miller E, McCloskey N, Cartwright K. Immunological response to conjugate vaccines in infants: follow up study. BMJ 1998;316:1570-1 https://doi.org/10.1136/bmj.316.7144.1570
- Scheifele D, Law B, Mitchell L, Ochnio J. Study of booster doses of two Haemophilus influenzae type b conjugate vaccines including their interchangeability. Vaccine 1996;14: 1399-406 https://doi.org/10.1016/S0264-410X(96)00086-2
- Kayhty H, Eskola J, Peltola H, Ronnberg PR, Kela E, Karanko V, et al. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991; 145:223-7
- Schlesinger Y, Granoff DM. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992;267:1489-94 https://doi.org/10.1001/jama.267.11.1489
- Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993;12:484-92 https://doi.org/10.1097/00006454-199306000-00006
- Anderson P, Johnston RB Jr, Smith DH. Human serum activities against Hemophilus influenzae, type b. J Clin Invest 1972;51:31-8 https://doi.org/10.1172/JCI106793
- Schneerson R, Rodrigues LP, Parke JC Jr, Robbins JB. Immunity to disease caused by Hemophilus influenzae, type b. II. Specificity and some biologic characteristics of 'natural', infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b. J Immunol 1971;107:1081-9.
- Nahm MH, Kim KH, Anderson P, Hetherington SV, Park MK. Functional capacities of clonal antibodies to Haemophilus influenzae type b polysaccharide. Infect Immun 1995; 3:2989-94
- WHO Expert Committee on Biological Standardization. Fortynth report. World Health Organ Tech Rep Ser 2000; 97:i-vi, 1-106
- Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus influenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun Dis Public Health 2003;6:55-8
- McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 2003; 61:1521-3
- Booy R, Heath PT, Slack MP, Begg N, Moxon ER. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997;349:1197-202 https://doi.org/10.1016/S0140-6736(96)06392-1
- Heath PT, McVernon J. The UK Hib vaccine experience. Arch Dis Child 2002;86:396-9 https://doi.org/10.1136/adc.86.6.396
- Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunisation programme, and changes to the meningitis C and Hib schedules. Euro Surveill 2006;11:E060302.4
- Rijkers GT, Vermeer-de Bondt PE, Spanjaard L, Breukels MA, Sanders EA. Return of Haemophilus influenzae type b infections. Lancet 2003;361:1563-4 https://doi.org/10.1016/S0140-6736(03)13201-1
- Banatvala J, Van Damme P, Van Hattum H. Boosters for hepatitis B. European Consensus Group on Hepatitis B Immunity. Lancet 2000;356:337-8
- Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005;11(Suppl 4):54-62 https://doi.org/10.1038/nm1216
- McVernon J, Johnson PD, Pollard AJ, Slack MP, Moxon ER. Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure. Arch Dis Child 2003;88:379-83 https://doi.org/10.1136/adc.88.5.379